(VIANEWS) – VISTIN PHARMA (VISTN.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| VISTIN PHARMA (VISTN.OL) | kr27.80 | 6.27% | 23.89% |
| BOIRON (BOI.PA) | €33.62 | 4.23% | 4.85% |
| VIRBAC (VIRP.PA) | €346.00 | 0.34% | 14.92% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. VISTIN PHARMA (VISTN.OL)
6.27% Forward Dividend Yield and 23.89% Return On Equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. Vistin Pharma ASA was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.54.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 18.05. Meaning, the purchaser of the share is investing kr18.05 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.89%.
Volatility
VISTIN PHARMA’s last week, last month’s, and last quarter’s current intraday variation average was 0.09%, 0.95%, and 1.64%.
VISTIN PHARMA’s highest amplitude of average volatility was 2.83% (last week), 2.30% (last month), and 1.64% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth declined by 0.6%, now sitting on 440.62M for the twelve trailing months.
Volume
Today’s last reported volume for VISTIN PHARMA is 3832 which is 89.05% below its average volume of 35006.
More news about VISTIN PHARMA.
2. BOIRON (BOI.PA)
4.23% Forward Dividend Yield and 4.85% Return On Equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.74.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 12.27. Meaning, the purchaser of the share is investing €12.27 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.85%.
Yearly Top and Bottom Value
BOIRON’s stock is valued at €33.62 at 17:30 EST, way under its 52-week high of €56.50 and way above its 52-week low of €29.30.
Volatility
BOIRON’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.64%, a negative 0.20%, and a positive 1.78%.
BOIRON’s highest amplitude of average volatility was 0.74% (last week), 1.04% (last month), and 1.78% (last quarter).
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 3, 2024, the estimated forward annual dividend rate is 1.35 and the estimated forward annual dividend yield is 4.23%.
More news about BOIRON.
3. VIRBAC (VIRP.PA)
0.34% Forward Dividend Yield and 14.92% Return On Equity
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Earnings Per Share
As for profitability, VIRBAC has a trailing twelve months EPS of €14.12.
PE Ratio
VIRBAC has a trailing twelve months price to earnings ratio of 24.5. Meaning, the purchaser of the share is investing €24.5 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.92%.
Volume
Today’s last reported volume for VIRBAC is 11037 which is 150.72% above its average volume of 4402.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VIRBAC’s stock is considered to be oversold (<=20).
More news about VIRBAC.
